OM:CRAD B

Stock Analysis Report

Executive Summary

C-Rad AB (publ), together with its subsidiaries, develops, manufactures, and sells systems with applications in radiation therapy for the treatment of cancer worldwide.

Snowflake

Fundamentals

Flawless balance sheet with acceptable track record.


Similar Companies

Share Price & News

How has C-Rad's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.5%

CRAD B

5.5%

SE Medical Equipment

2.1%

SE Market


1 Year Return

24.8%

CRAD B

34.0%

SE Medical Equipment

12.1%

SE Market

Return vs Industry: CRAD B underperformed the Swedish Medical Equipment industry which returned 34% over the past year.

Return vs Market: CRAD B exceeded the Swedish Market which returned 12.1% over the past year.


Shareholder returns

CRAD BIndustryMarket
7 Day1.5%5.5%2.1%
30 Day3.9%1.3%1.6%
90 Day-15.0%1.6%3.7%
1 Year24.8%24.8%35.4%34.0%16.8%12.1%
3 Year215.0%215.0%54.9%36.6%32.2%12.4%
5 Year144.6%141.6%72.9%44.6%62.8%28.3%

Price Volatility Vs. Market

How volatile is C-Rad's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is C-Rad undervalued compared to its fair value and its price relative to the market?

42.77x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: CRAD B (SEK33.7) is trading above our estimate of fair value (SEK32.81)

Significantly Below Fair Value: CRAD B is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: CRAD B is good value based on its PE Ratio (42.8x) compared to the Medical Equipment industry average (44x).

PE vs Market: CRAD B is poor value based on its PE Ratio (42.8x) compared to the Swedish market (16.9x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CRAD B's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CRAD B is overvalued based on its PB Ratio (10.8x) compared to the SE Medical Equipment industry average (4.4x).


Next Steps

Future Growth

How is C-Rad forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

24.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as C-Rad has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has C-Rad performed over the past 5 years?

31.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: CRAD B has become profitable over the past 5 years, growing earnings by 31% per year.

Accelerating Growth: CRAD B has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: CRAD B has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (17.3%).


Return on Equity

High ROE: CRAD B's Return on Equity (25.4%) is considered high.


Return on Assets

ROA vs Industry: CRAD B has a higher Return on Assets than the Medical Equipment industry average last year.


Return on Capital Employed

ROCE Improving: CRAD B's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is C-Rad's financial position?


Financial Position Analysis

Short Term Liabilities: CRAD B's short term assets (SEK108.4M) exceeds its short term liabilities (SEK48.8M)

Long Term Liabilities: CRAD B's short term assets (108.4M) exceeds its long term liabilities (32.7M)


Debt to Equity History and Analysis

Debt Level: CRAD B is debt free.

Reducing Debt: CRAD B has no debt compared to 5 years ago when its debt to equity ratio was 23.3%.

Debt Coverage: CRAD B has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: CRAD B has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: CRAD B has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if CRAD B's debt is covered by short term assets.


Next Steps

Dividend

What is C-Rad's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.8%markettop25%4.6%industryaverage1.1%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate CRAD B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CRAD B's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if CRAD B's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CRAD B's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CRAD B's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

What is the CEO of C-Rad's salary, the management and board of directors tenure and is there insider trading?

4.5yrs

Average management tenure


CEO

Tim Thurn (38yo)

6.3yrs

Tenure

kr2,284,000

Compensation

Mr. Tim Thurn has been the Chief Executive Officer and President of C-Rad AB since July 1, 2013. Mr. Thurn has been the Chief Executive Officer of C-Rad Imaging AB since 2014. He served as the President at ...


CEO Compensation Analysis

Compensation vs. Market: Tim's total compensation ($USD237.11K) is about average for companies of similar size in the Swedish market ($USD123.35K).

Compensation vs Earnings: Tim's compensation has been consistent with company performance over the past year.


Management Age and Tenure

4.5yrs

Average Tenure

38yo

Average Age

Experienced Management: CRAD B's management team is considered experienced (4.5 years average tenure).


Board Age and Tenure

3.3yrs

Average Tenure

57yo

Average Age

Experienced Board: CRAD B's board of directors are considered experienced (3.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Buykr678,00311 May 19
Lars Nyberg
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares18,221
Max Pricekr37.21

Ownership Breakdown


Management Team

  • Tim Thurn (38yo)

    CEO & President

    • Tenure: 6.3yrs
    • Compensation: kr2.28m
  • Ling Zhang (48yo)

    Global Marketing Manager

    • Tenure: 4.5yrs
  • Therése Björklund (38yo)

    Chief Financial Officer

    • Tenure: 0.6yrs

Board Members

  • Lars Nyberg (68yo)

    Chairman of the Board

    • Tenure: 3.3yrs
    • Compensation: kr400.00k
  • Åsa Hedin (57yo)

    Director

    • Tenure: 2.8yrs
    • Compensation: kr200.00k
  • Kicki Wallje-Lund (66yo)

    Director

    • Tenure: 4.8yrs
    • Compensation: kr200.00k
  • Per Hamberg (46yo)

    Director

    • Tenure: 6.4yrs
    • Compensation: kr200.00k
  • David Sjöström (45yo)

    Director

    • Tenure: 2.4yrs
    • Compensation: kr200.00k

Company Information

C-Rad AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: C-Rad AB (publ)
  • Ticker: CRAD B
  • Exchange: OM
  • Founded: 2004
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr1.045b
  • Shares outstanding: 31.02m
  • Website: https://www.c-rad.se

Number of Employees


Location

  • C-Rad AB (publ)
  • Bredgränd 18
  • Uppsala
  • Uppsala County
  • 753 20
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CRAD BOM (OMX Nordic Exchange Stockholm)YesClass B SharesSESEKJul 2007

Biography

C-Rad AB (publ), together with its subsidiaries, develops, manufactures, and sells systems with applications in radiation therapy for the treatment of cancer worldwide. The company operates through two seg ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/21 21:01
End of Day Share Price2019/10/21 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.